Replicor to Present Pre-Clinical and Updated Clinical Data on REP 2139-Ca Based Combination Therapy in Chronic HBV and HBV / HDV Co-Infection at APASL 2016
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will present preclinical and updated clinical data on REP 2139-Ca based combination therapies in HBV infection and HBV / HDV co-infection at the 25th Annual Meeting of the Asia Pacific Association for the Study of the Liver to be held from February 20 -24, 2016 in Toyko, Japan. Three presentations on Replicor technology will be made during the meeting:
HBV RNA is emerging as a potential new marker of viremia in patients with HBV infection. In patients with HBeAg positive HBV infection, treatment with REP 2139-Ca and immunotherapy (in the REP 102 protcol), not only leads to reduction / clearance of HBsAg and HBV DNA and the appearance of anti-HBs but also to reduction of HBV RNA as well. The characterization of the HBV RNA response in the REP 102 protocol was done in collaboration with the lab of Dr. Hendrik Reesink at the Amsterdam Medical Center, and will be presented by Dr. Reesink in the Presidential Plenary Session on February 22nd .
An update on the clinical response data from HBV /HDV co-infected patients completing REP 2139-Ca / peg-interferon combination therapy and transitioning to peg-interferon monotherapy in the REP 301 protocol will be presented in an oral presentation on Feb 22nd (O-130).
A poster presentation on the effects of combined treatment with REP 2139-Ca and tenofovir disoproxil fumarate and entecavir on serum and liver virema in vivo will be presented on Feb 22nd (P-0329).
These pre-clinical and clinical studies continue to advance Replicor’s understanding of the antiviral effects of REP 2139-Ca based combination therapies and how these can be used to benefit patients with HBV infection or HBV / HDV co-infection.
For the APASL 2016 meeting and preliminary program:
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com .
For Replicor Inc.
Alexandra Peterson, 212-508-9709
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
VA-CTA17.10.2017 18:21 | pressemeddelelse
CES Unveiled Amsterdam to Feature IoT, Smart Cities and Robotics
CA-DROPBOX17.10.2017 18:02 | pressemeddelelse
Dropbox giver enkeltpersoner kraftfulde erhvervsværktøjer med Dropbox Professional
ZTE-CORPORATION17.10.2017 16:42 | pressemeddelelse
The New Foldable Smartphone ZTE Axon M with Dual Screens Transforms the Mobile Experience for Consumers
EUNETWORKS17.10.2017 16:02 | pressemeddelelse
euNetworks Partners with Cloudwirx
MUREX17.10.2017 16:02 | pressemeddelelse
Murex to Offer Cloud-Based Trading and Risk Management Solutions
ASSECO-SEE17.10.2017 16:01 | pressemeddelelse
Asseco SEE’s Enterprise Fraud Monitoring & Prevention Solution InACT® is in GarantiBank NV
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum